Tourette SyndromeBioTicNCT06909656
Multimodal Electrophysiological Study of Cortico-subcortical Biomarkers of Tics in Tourette Syndrome
A study testing Multimodal electrophysiological recordings in people with Tourette Syndrome, run by University Hospital, Bordeaux at 1 site in France.
Trial summary
Tourette syndrome (TS) is a complex neurodevelopmental disorder characterized by the occurrence of involuntary movements (motor tics) and vocalizations (phonic tics). The onset of TS is usually in childhood, and the prevalence of TS is estimated between 0.3 and 0.9% before the age of 18, decreasing progressively after… Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Tourette Syndrome
- What is being tested?
- Multimodal electrophysiological recordings
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteFrance
- Study dates
- 17 Feb 2025to 17 Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patient at least 16 years old.
- Disabling and drug-resistant Tourette's syndrome.
- Receiving deep brain stimulation treatment with implantation of the PERCEPT™ Device as part of their medical management.
- Normal brain MRI.
- Subject affiliated or beneficiary of a social security system.
- Free and informed consent of the patient and, for minors, of the minor and at least one parental authority.
Who cannot join
- Major depressive syndrome (Beck Depression Inventory (BDI-II) > 20).
- MRI showing significant brain atrophy or significant hyperintensities.
- Pregnant or nursing mothers.
- Person unable to give personal consent.
- Person subject to a legal protection measure (curatorship, guardianship) or placed under court protection.
- Patient included in another research protocol with an interdiction of participation to another research or in an exclusion period
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU de Bordeaux
Bordeaux, 33076
Edouard COURTIN, Dr, 05 57 82 12 42, edouard.courtin@chu-bordeaux.fr
About this study
Tourette syndrome (TS) is a complex neurodevelopmental disorder characterized by the occurrence of involuntary movements (motor tics) and vocalizations (phonic tics). The onset of TS is usually in childhood, and the prevalence of TS is estimated between 0.3 and 0.9% before the age of 18, decreasing progressively after that age. Most patients also suffer from associated psychiatric comorbidities (ADHD, OCD, mood disorders). Although the cause of TS remains unknown, the preferred hypothesis is the interaction of predisposing genetic factors and precipitating environmental factors (perinatal accidents, infectious diseases). From a pathophysiological point of view, it is widely demonstrated by structural, electrophysiological studies, functional neuroimaging, as well as by different animal models, that dysfunctions of the cortico-striato-pallido-thalamo-cortical loops (responsible for the regulation of movements, cognitive processes, and emotions) play a major role in the genesis of tics. Deep brain stimulation (DBS) treatment can be proposed as an invasive therapy in patients with severe TS resistant to usual treatments (psychotherapy, pharmacological treatments). In a well-selected population of drug-resistant patients, DBS allows an estimated overall improvement of 30 to 50% in the YGTSS score. The deep brain stimulation method currently used in TS is based on continuous (24/7) and undifferentiated stimulation (fixed electrical intensity). This stimulation paradigm, devoid of adaptability to the patient's symptoms, could be at the origin of undesirable effects (related to the modulation of physiological signals), of a sub-optimal efficiency, or of an unnecessary overuse of the stimulator's capacities (battery depletion). The development of new deep brain stimulation paradigms ("closed-loop stimulation"), allowing the identification of pathological neuronal activity and the dynamic adaptation of stimulation parameters to these neuronal signals, requires reliable and reproducible pathological biomarker, correlated with the occurrence of tics.
However, in TS, electrophysiological abnormalities are still not well characterized, and most of the work published on the subject were based on intraoperative recordings and needs to be confirmed on recordings at a distance from the surgery before its potential use in closed-loop stimulation paradigms. Indeed, during the first weeks after surgery, different factors tend to modify the electrophysiological signals.
Read more
Several questions arise at the end of this healing period:
- Are these pathological oscillations (distinct from the brain oscillations induced by physiological voluntary movement) still detectable weeks after the surgery?
- What are the temporal dynamics of these oscillations around a tic?
- What is the spatial topography of these oscillations within the GPi?
- Is there a strong inter-individual variability?
- How are changes in cortical activity associated with these subcortical oscillations?
- Are the modulations of pallidal activity alone sufficient to predict the occurrence of a tic? Thus, our study aims to define precisely the cortico-subcortical activity concomitant with the occurrence of a tic, and to identify reliable and reproducible biomarker(s) associated with tics in TS.
In order to specify these biomarker(s), their temporal correlation to tic occurrence, their spatial distribution, as well as the dynamics and cortico-subcortical coherence of the identified abnormalities, we propose a prospective study on 10 patients with severe and drug-resistant TS, treated by bi-pallidal deep brain stimulation as part of routine care (no device implantation as part of the research).
An evaluation of pallidal LFP synchronized with a high-resolution video-electroencephalography recording (128 to 256 sensors) will be performed at a distance (M+[3-48]) from surgery, in order to determine the variations in pallidal and electroencephalographic activity surrounding the occurrence of tics. A control condition with voluntary ("tic-like") movement will be carried out in a second time, to distinguish the modifications related to the voluntary movement from those related to the occurrence of a tic. A reconstruction of the electrode positioning will be performed using the LeadDBS pipeline, and individual and group analyses will be performed to specify the mapping of pathological oscillations within the pallidum and throughout the cerebral cortex.
- Conditions
- Tourette Syndrome
- Being tested
- Multimodal electrophysiological recordings
- Keywords
- Tourette Syndrome, Local field potentials, Deep Brain Stimulation
- Medical subject headings
- Tourette Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multimodal electrophysiological recordingsOther
Intervention(s): Multimodal electrophysiological recordings (Local field potentials, High-Resolution Electroencephalogram, Electromyogram) coupled with video analysis, in experimental condition, in uncontrolled tic and voluntary ("tic-like") movement.
| Study group | Role | What they receive |
|---|---|---|
| Patient with Tourette's syndrome | Experimental | Patient with Tourette's syndrome receiving deep brain stimulation treatment with implantation of the PERCEPT™ device as part of their medical management. Receives: Other: Multimodal electrophysiological recordings |
What is being measured
The primary outcome is the main question the study is designed to answer.
Spectral power
Pallidal spectral power in the 2 clinical conditions (i) Tic [pre-tic-post] and (ii) Voluntary ("tic-like") movement [pre-movement-post] respectively.
Measured: Inclusion visit
Secondary outcomes (12)
Electrode localization
Measured: Inclusion visit
Pallidal and cortical spectral power
Pallidal and cortical spectral power analysis in the 2 clinical conditions (i) Tic and (ii) Voluntary movement ("tic-like").
Measured: Inclusion visit
Pallidal and cortical time-frequency
the 2 clinical conditions (i) Tic and (ii) Voluntary movement ("tic-like").
Measured: Inclusion visit
Cortico-subcortical coherence
Cortico-subcortical coherence of the recorded oscillations.
Measured: Inclusion visit
Cortico-subcortical phase synchronization
Cortico-subcortical phase synchronization of the recorded oscillations.
Measured: Inclusion visit
Cortico-subcortical phase-amplitude coupling
Cortico-subcortical phase-amplitude coupling of the recorded oscillations.
Measured: Inclusion visit
Adult ADHD Self-Report Scale (ASRS) Score
Used to assess symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults, it consists of 18 items.
Total score of 0 to 14: Low probability of ADHD.
Total score of 15 to 24: Intermediate probability that the person exhibits symptoms of ADHD.
Total score of 25 to 36: Suggests a high probability of ADHD.
Measured: Inclusion visit
Adult ADHD Self-Report Scale (ASRS) Score
Used to assess symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults, it consists of 18 items.
Total score of 0 to 14: Low probability of ADHD.
Total score of 15 to 24: Intermediate probability that the person exhibits symptoms of ADHD.
Total score of 25 to 36: Suggests a high probability of ADHD.
Measured: One month before inclusion
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Score
Considered as the reference scale for evaluating obsessive-compulsive disorders. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is designed to assess both the types of symptoms and their severity. The Y-BOCS evaluates 10 items, each rated from 0 (no symptoms) to 4 (extreme symptoms).
The total score ranges as follows:
0 to 7: Normal
8 to 15: Mild
16 to 23: Moderate
24 to 31: Severe
32 to 40: Very severe
Measured: Inclusion visit
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Score
Considered as the reference scale for evaluating obsessive-compulsive disorders. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is designed to assess both the types of symptoms and their severity. The Y-BOCS evaluates 10 items, each rated from 0 (no symptoms) to 4 (extreme symptoms).
The total score ranges as follows:
0 to 7: Normal
8 to 15: Mild
16 to 23: Moderate
24 to 31: Severe
32 to 40: Very severe
Measured: One month before inclusion
Yale Global Tic Severity Scale (YGTSS) Score
semi-structured clinical interview scale that is considered the gold standard for assessing the severity of tics in both children and adults. The YGTSS evaluates the number, frequency, intensity, complexity, and distress associated with motor and vocal tics over the past week. Each domain is assessed on a 6-point scale (from 0 to 5), with a separate, more global score for "overall disability" concerning the individual's daily life and activities.
Five sub-scores can be extracted:
The total "motor tic" score (from 0 to 25)
The total "vocal tic" score (from 0 to 25)
The total "tic" score (sum of the two previous scores)
The overall disability assessment (one item; from 0 to 50)
The global severity score (from 0 to 100)
Measured: Inclusion visit
Yale Global Tic Severity Scale (YGTSS) Score
semi-structured clinical interview scale that is considered the gold standard for assessing the severity of tics in both children and adults. The YGTSS evaluates the number, frequency, intensity, complexity, and distress associated with motor and vocal tics over the past week. Each domain is assessed on a 6-point scale (from 0 to 5), with a separate, more global score for "overall disability" concerning the individual's daily life and activities.
Five sub-scores can be extracted:
The total "motor tic" score (from 0 to 25)
The total "vocal tic" score (from 0 to 25)
The total "tic" score (sum of the two previous scores)
The overall disability assessment (one item; from 0 to 50)
The global severity score (from 0 to 100)
Measured: One month before inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Apr 2025
- Study start17 Feb 2025
- Primary completion17 Feb 2027 (estimated)
- Study completion17 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Tourette SyndromeStudies of the same condition, open and under way.
- More trials run by University Hospital, BordeauxThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Bordeaux
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Edouard COURTIN, Dr, Principal investigator, University Hospital, Bordeaux
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06909656
- Sponsor's protocol ID
- CHUBX 2023/84
- Acronym
- BioTic
- Status last verified
- Apr 2025
- First submitted
- 24 Mar 2025
- Last updated
- 3 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multimodal Electrophysiological Study of Cortico-subcortical Biomarkers of Tics in Tourette Syndrome
- ClinicalTrials.gov ID
- NCT06909656
- Acronym / sponsor ID
- BioTic / CHUBX 2023/84
- Conditions
- Tourette Syndrome
- Keywords
- Tourette Syndrome, Local field potentials, Deep Brain Stimulation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- University Hospital, BordeauxUniversity, hospital or other
- Study start
- 17 Feb 2025 (actual)
- Primary completion
- 17 Feb 2027 (estimated)
- Study completion
- 17 Feb 2027 (estimated)
- First posted
- 3 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Tourette syndrome (TS) is a complex neurodevelopmental disorder characterized by the occurrence of involuntary movements (motor tics) and vocalizations (phonic tics). The onset of TS is usually in childhood, and the prevalence of TS is estimated between 0.3 and 0.9% before the age of 18, decreasing progressively after that age. Most patients also suffer from associated psychiatric comorbidities (ADHD, OCD, mood disorders). Although the cause of TS remains unknown, the preferred hypothesis is the interaction of predisposing genetic factors and precipitating environmental factors (perinatal accidents, infectious diseases). From a pathophysiological point of view, it is widely demonstrated by structural, electrophysiological studies, functional neuroimaging, as well as by different animal models, that dysfunctions of the cortico-striato-pallido-thalamo-cortical loops (responsible for the regulation of movements, cognitive processes, and emotions) play a major role in the genesis of tics. Deep brain stimulation (DBS) treatment can be proposed as an invasive therapy in patients with severe TS resistant to usual treatments (psychotherapy, pharmacological treatments). In a well-selected population of drug-resistant patients, DBS allows an estimated overall improvement of 30 to 50% in the YGTSS score. The deep brain stimulation method currently used in TS is based on continuous (24/7) and undifferentiated stimulation (fixed electrical intensity). This stimulation paradigm, devoid of adaptability to the patient's symptoms, could be at the origin of undesirable effects (related to the modulation of physiological signals), of a sub-optimal efficiency, or of an unnecessary overuse of the stimulator's capacities (battery depletion). The development of new deep brain stimulation paradigms ("closed-loop stimulation"), allowing the identification of pathological neuronal activity and the dynamic adaptation of stimulation parameters to these neuronal signals, requires reliable and reproducible pathological biomarker, correlated with the occurrence of tics.
However, in TS, electrophysiological abnormalities are still not well characterized, and most of the work published on the subject were based on intraoperative recordings and needs to be confirmed on recordings at a distance from the surgery before its potential use in closed-loop stimulation paradigms. Indeed, during the first weeks after surgery, different factors tend to modify the electrophysiological signals.
Several questions arise at the end of this healing period:
- Are these pathological oscillations (distinct from the brain oscillations induced by physiological voluntary movement) still detectable weeks after the surgery?
- What are the temporal dynamics of these oscillations around a tic?
- What is the spatial topography of these oscillations within the GPi?
- Is there a strong inter-individual variability?
- How are changes in cortical activity associated with these subcortical oscillations?
- Are the modulations of pallidal activity alone sufficient to predict the occurrence of a tic? Thus, our study aims to define precisely the cortico-subcortical activity concomitant with the occurrence of a tic, and to identify reliable and reproducible biomarker(s) associated with tics in TS.
In order to specify these biomarker(s), their temporal correlation to tic occurrence, their spatial distribution, as well as the dynamics and cortico-subcortical coherence of the identified abnormalities, we propose a prospective study on 10 patients with severe and drug-resistant TS, treated by bi-pallidal deep brain stimulation as part of routine care (no device implantation as part of the research).
An evaluation of pallidal LFP synchronized with a high-resolution video-electroencephalography recording (128 to 256 sensors) will be performed at a distance (M+[3-48]) from surgery, in order to determine the variations in pallidal and electroencephalographic activity surrounding the occurrence of tics. A control condition with voluntary ("tic-like") movement will be carried out in a second time, to distinguish the modifications related to the voluntary movement from those related to the occurrence of a tic. A reconstruction of the electrode positioning will be performed using the LeadDBS pipeline, and individual and group analyses will be performed to specify the mapping of pathological oscillations within the pallidum and throughout the cerebral cortex.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patient with Tourette's syndrome | Experimental | Other: Multimodal electrophysiological recordingsPatient with Tourette's syndrome receiving deep brain stimulation treatment with implantation of the PERCEPT™ device as part of their medical management. |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (6 listed)
- Patient at least 16 years old.
- Disabling and drug-resistant Tourette's syndrome.
- Receiving deep brain stimulation treatment with implantation of the PERCEPT™ Device as part of their medical management.
- Normal brain MRI.
- Subject affiliated or beneficiary of a social security system.
Key exclusion criteria (6 listed)
- Major depressive syndrome (Beck Depression Inventory (BDI-II) > 20).
- MRI showing significant brain atrophy or significant hyperintensities.
- Pregnant or nursing mothers.
- Person unable to give personal consent.
- Person subject to a legal protection measure (curatorship, guardianship) or placed under court protection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multimodal electrophysiological recordingsIntervention(s): Multimodal electrophysiological recordings (Local field potentials, High-Resolution Electroencephalogram, Electromyogram) coupled with video analysis, in experimental condition, in uncontrolled tic and voluntary ("tic-like") movement. | Other | Patient with Tourette's syndrome |
Primary outcome
Spectral power
Time frame: Inclusion visit
Pallidal spectral power in the 2 clinical conditions (i) Tic [pre-tic-post] and (ii) Voluntary ("tic-like") movement [pre-movement-post] respectively.
12 secondary outcomes
Electrode localization
Time frame: Inclusion visit
Pallidal and cortical spectral power
Time frame: Inclusion visit
Pallidal and cortical time-frequency
Time frame: Inclusion visit
Cortico-subcortical coherence
Time frame: Inclusion visit
Cortico-subcortical phase synchronization
Time frame: Inclusion visit
Cortico-subcortical phase-amplitude coupling
Time frame: Inclusion visit
Adult ADHD Self-Report Scale (ASRS) Score
Time frame: Inclusion visit
Adult ADHD Self-Report Scale (ASRS) Score
Time frame: One month before inclusion
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Score
Time frame: Inclusion visit
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Score
Time frame: One month before inclusion
Yale Global Tic Severity Scale (YGTSS) Score
Time frame: Inclusion visit
Yale Global Tic Severity Scale (YGTSS) Score
Time frame: One month before inclusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2025.
- Individual participant dataSharing planned: No
Related trials for Tourette Syndrome
Not yet recruiting
Evaluating and Promoting Resilience in Adolescents With Tourette Syndrome
Tourette Syndrome, Tic Disorders
Not yet recruiting
Transcutaneous Auricular Vagus Nerve Stimulation for Chronic Tic Disorders/Tourette's Syndrome in Children and Adolescents
Tourette Syndrome, Chronic Tic Disorder
Recruiting
Deep Brain Stimulation Therapy in Movement Disorders
Parkinson's Disease
Recruiting
Exploring the Role of Neuroactive Steroids in Tourette Syndrome
Tourette Syndrome in Children
Active, not recruiting
Tourette Deep Brain Stimulation (DBS) Target Detection & Suppression
Tourette Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Edouard COURTIN, Dr principal investigator
University Hospital, Bordeaux
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multimodal electrophysiological recordings in people with Tourette Syndrome, run by University Hospital, Bordeaux at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Edouard COURTIN, Dr (05 57 82 12 42, edouard.courtin@chu-bordeaux.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Spectral power (time frame: Inclusion visit). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2025.